Instrument Inactif

Communiqués Dipexium Pharmaceuticals Inc Nasdaq

Actions

US25456J1043

Communiqués

27/05/23	PLx Pharma : Material Agreement - Form 8-K	PU
13/04/23	PLx Pharma : Bankruptcy - Form 8-K	PU
13/04/23	PLX PHARMA INC. : Bankruptcy or Receivership, Financial Statements and Exhibits (form 8-K)	AQ
12/04/23	PLX PHARMA INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
12/04/23	PLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE® and Substantially All of its Assets	AQ
11/04/23	PLx Pharma Inc. Receives Nasdaq Delisting Notice	AQ
10/04/23	PLX PHARMA INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K)	AQ
08/03/23	PLX PHARMA INC. : Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
13/02/23	PLX PHARMA INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
20/01/23	PLX PHARMA INC. : Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
10/11/22	PLX PHARMA INC. : Results of Operations and Financial Condition, Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	AQ
10/11/22	PLX PHARMA INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
10/11/22	PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Update	AQ
26/10/22	PLx Pharma Inc. to Report Third Quarter 2022 Financial Results on November 11, 2022, and Provide Business Update	AQ
07/10/22	PLX PHARMA INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K)	AQ
12/09/22	Baseball Legend John Smoltz Featured on PLx Pharma’s Social Channels	AQ
12/08/22	PLX PHARMA INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
12/08/22	PLx Pharma : Reports Second Quarter 2022 Results and Provides Business Update - Form 8-K	PU
12/08/22	PLX PHARMA INC. : Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
12/08/22	Survey: Cardiovascular Patients on Aspirin Therapy Prefer VAZALORE® 81 mg	AQ
12/08/22	PLx Pharma Inc. Reports Second Quarter 2022 Results and Provides Business Update	AQ
27/07/22	PLx Pharma Inc. to Report Second Quarter 2022 Financial Results August 12, 2022, and Provide Business Update	AQ
01/06/22	PLx Pharma Inc. to Present at JMP Securities 2022 Life Sciences Conference on June 15, 2022	AQ
20/05/22	PLx Pharma Inc. Showcases VAZALORE at The Annual Meeting of The Society for Cardiovascular Angiography and Interventions	AQ
13/05/22	PLX PHARMA INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ